View ValuationGetinge 将来の成長Future 基準チェック /26Getinge利益と収益がそれぞれ年間11.8%と4.4%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に10.6% 12.2%なると予測されています。主要情報11.8%収益成長率12.21%EPS成長率Medical Equipment 収益成長14.0%収益成長率4.4%将来の株主資本利益率10.57%アナリストカバレッジGood最終更新日01 Jun 2026今後の成長に関する最新情報お知らせ • Oct 21Getinge AB (Publ) Reaffirms Earnings Guidance for the Year 2025Getinge AB (publ) reaffirmed earnings guidance for the year 2025. The company remain with expectation for organic net sales growth to be in the range of 2% to 5% and long-term financial target of over 12% EPS growth is also intact despite the headwind from tariffs and currency.すべての更新を表示Recent updatesお知らせ • Jun 04Getinge Launches Vasoview Hemopro 3 Endoscopic Vessel Harvesting SystemGetinge announced the launch of the Vasoview Hemopro 3 Endoscopic Vessel Harvesting (EVH) System, including the Hemopro 3 Harvesting Tool and dedicated Hemopro 3 Power Supply. The system represents the latest evolution of Getinge's EVH platform, enhancing decades of experience supporting coronary artery bypass grafting (CABG) procedures. Endoscopic vessel harvesting is a minimally invasive technique used to obtain blood vessels, most commonly the saphenous vein or radial artery, for use in CABG surgery. Vessel harvesting plays a critical role in procedural success, as conduit quality and incision-related complications can significantly impact outcomes and recovery. Compared with traditional open harvesting methods, EVH has been associated with reduced wound complications, less postoperative pain, faster recovery, and improved cosmetic results. Getinge has completed an Initial Launch of the Vasoview Hemopro 3 EVH System and has received valuable, positive customer feedback. Getinge has continuously refined EVH technology with a focus on preserving conduit quality while improving the patient and clinician experience. Through close collaboration with vessel harvesting specialists, Getinge has advanced EVH technology in a deliberate, user-driven way, ensuring solutions evolve alongside clinical practice. The Vasoview Hemopro 3 system incorporates targeted enhancements across ergonomics, energy control, visualization, and workflow efficiency, informed by input from more than 100 vessel harvesting specialists worldwide. A redesigned Harvesting Tool features an ergonomic, game-controller-style handle and a soft-touch Activation Toggle that allows activation with minimal force and multiple hand positions, supporting clinician comfort and control throughout the procedure. The system also introduces simplified connectivity through an integrated Harvesting Tool Power Cable, providing a one-click connection to the new Vasoview Hemopro 3 Power Supply and eliminating the need for extension cable sterilization. The dedicated Power Supply is designed to deliver consistent energy and promote efficient cut-and-cautery performance with minimal downtime. Hemopro 3 includes features which support consistent visibility, safety, and workflow efficiency during EVH. Vasoview Hemopro 3 is launching in the U.S., with a training supported rollout available for U.S. customers. Getinge plans a phased expansion outside the U.S., with availability in additional markets to follow based on regulatory approvals and market readiness. Vasoview Hemopro 2 will continue to be available as Getinge rollout availability of Vasoview Hemopro 3.Recent Insider Transactions • May 31CEO, President & Director recently bought €436k worth of stockOn the 29th of May, Mattias Perjos bought around 25k shares on-market at roughly €17.43 per share. This transaction amounted to 12% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Mattias has been a buyer over the last 12 months, purchasing a net total of €715k worth in shares.Valuation Update With 7 Day Price Move • May 22Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to €18.75, the stock trades at a forward P/E ratio of 18x. Average forward P/E is 19x in the Medical Equipment industry in Italy. Total returns to shareholders of 8.3% over the past year. Simply Wall St's valuation model estimates the intrinsic value at €32.79 per share.New Risk • May 15New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Italian stocks, typically moving 7.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (7.2% average weekly change).お知らせ • Apr 22+ 1 more updateGetinge AB (publ) Approves Dividend, Payable from April 28, 2026Getinge AB (publ) approved the Dividend payment at its Annual General Meeting held on April 21, 2026. In accordance with the proposal by the Board of Directors and the CEO, the AGM resolved to declare a dividend of SEK 4.75 per share. April 23, 2026 was determined as record date for dividend. The dividend is expected to be distributed by Euroclear Sweden AB starting April 28, 2026.お知らせ • Apr 10Getinge AB (publ) (OM:GETI B) acquired Pennamed Limited.Getinge AB (publ) (OM:GETI B) acquired Pennamed Limited on April 8, 2026. The acquisition strengthens Getinge’s offering to endoscopy units across the United Kingdom (UK) by combining Pennamed’s established consumables portfolio and strong customer relationships with Getinge’s expertise in endoscope reprocessing, infection control, and washer-disinfector technology. Getinge and Pennamed has combined 350 employees. Abi Godfrey, Alex Parry and Matt Harvey of Grant Thornton UK LLP acted as accountants for Pennamed Limited. Emma Orriss and Nigel Beckwith of Gosschalks LLP acted as legal advisors for Pennamed Limited. Covington & Burling Llp acted as legal advisor and Ernst & Young AB acted as accountant for Getinge AB. Getinge AB (publ) (OM:GETI B) completed the acquisition of Pennamed Limited on April 8, 2026.お知らせ • Mar 26+ 3 more updatesGetinge AB (publ) to Report Q2, 2026 Results on Jul 17, 2026Getinge AB (publ) announced that they will report Q2, 2026 results on Jul 17, 2026お知らせ • Mar 12Getinge AB (publ) Announces Malin Persson Declines Re-Election as Board Member, Effective April 21, 2026Getinge AB (publ) at its Annual General Meeting to be held on April 21, 2026, announced Malin Persson has declined re-election as board member.Declared Dividend • Feb 24Dividend of kr4.75 announcedShareholders will receive a dividend of kr4.75. Ex-date: 22nd April 2026 Payment date: 28th April 2026 Dividend yield will be 25%, which is higher than the industry average of 1.7%. Sustainability & Growth Dividend is covered by both earnings (57% earnings payout ratio) and cash flows (49% cash payout ratio). The dividend has increased by an average of 5.4% per year over the past 10 years. However, payments have been volatile during that time. EPS is expected to grow by 47% over the next 3 years, which should provide support to the dividend and adequate earnings cover.Board Change • Feb 24Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 4 experienced directors. 7 highly experienced directors. Director Ulrika Dellby was the last director to join the board, commencing their role in 2025. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.お知らせ • Jan 28Getinge AB (publ), Annual General Meeting, Apr 21, 2026Getinge AB (publ), Annual General Meeting, Apr 21, 2026.お知らせ • Jan 27Getinge AB (Publ) Proposes DividendGetinge AB (publ) announced the proposal of dividend per share of SEK 4.75 (4.60).お知らせ • Dec 19Getinge AB Announces Malin Persson Declines Re-Election to the BoardGetinge AB announced that Malin Persson, a board member since 2014, has announced that she will not be available for re-election to the board in 2026.Board Change • Dec 11Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 4 experienced directors. 7 highly experienced directors. Director Ulrika Dellby was the last director to join the board, commencing their role in 2025. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Board Change • Nov 19Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 4 experienced directors. 7 highly experienced directors. Director Ulrika Dellby was the last director to join the board, commencing their role in 2025. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.お知らせ • Oct 21Getinge AB (Publ) Reaffirms Earnings Guidance for the Year 2025Getinge AB (publ) reaffirmed earnings guidance for the year 2025. The company remain with expectation for organic net sales growth to be in the range of 2% to 5% and long-term financial target of over 12% EPS growth is also intact despite the headwind from tariffs and currency.Reported Earnings • Jul 21Second quarter 2025 earnings released: EPS: kr1.92 (vs kr1.88 in 2Q 2024)Second quarter 2025 results: EPS: kr1.92 (up from kr1.88 in 2Q 2024). Revenue: kr8.24b (flat on 2Q 2024). Net income: kr524.0m (up 2.1% from 2Q 2024). Profit margin: 6.4% (up from 6.2% in 2Q 2024). Revenue is forecast to grow 4.6% p.a. on average during the next 3 years, compared to a 6.5% growth forecast for the Medical Equipment industry in Italy.お知らせ • Jul 02Getinge AB (publ)(OM:GETI B) dropped from OMX Stockholm 30 IndexGetinge AB (publ) has been dropped from the OMX OMX Stockholm 30 Indexお知らせ • Apr 23+ 1 more updateGetinge AB (publ) Approves Dividend, Payable on April 29, 2025Getinge AB (publ) at its AGM held on April 22, 2025 approved dividend of SEK 4.60 per share. April 24, 2025 was determined as record date for dividend. The dividend is expected to be distributed by Euroclear Sweden AB starting Tuesday April 29, 2025.お知らせ • Mar 28+ 1 more updateGetinge AB (publ) to Report Q3, 2025 Results on Oct 21, 2025Getinge AB (publ) announced that they will report Q3, 2025 results on Oct 21, 2025お知らせ • Mar 18Getinge Introduces Neural Pressure Support for the Servo-U Ventilator SystemGetinge announces the launch of its latest innovation in ICU ventilation – Neural Pressure Support (NPS) – available for both invasive and non-invasive ventilation. Building on its most personalized ventilation modes, NAVA and NIV NAVA, these two new NPS modes offer clinicians more options to provide personalized ventilation that aims to protect both the lungs and diaphragm. For years, Getinge has been market-driving when it comes to developing first-of-its-kind intensive care ventilation modes. The medtech company is introducing NPS and NIV NPS to widen its neurally controlled ventilation offering. The new Neural Pressure Support modes give clinicians the opportunity to deliver classical pressure support ventilation, enhanced with neural trigger and breath termination in synchrony with diaphragmatic muscle activity. This may be particularly beneficial for complex and challenging ICU patient groups, such as obstructive COPD patients requiring instant synchronization and fast pressurization, and restrictive ARDS patients with stiff lungs and an excessive respiratory drive.お知らせ • Jan 29Getinge AB (publ), Annual General Meeting, Apr 22, 2025Getinge AB (publ), Annual General Meeting, Apr 22, 2025. Location: halmstad Swedenお知らせ • Dec 10Getinge AB (publ) to Report Q1, 2025 Results on Apr 22, 2025Getinge AB (publ) announced that they will report Q1, 2025 results on Apr 22, 2025業績と収益の成長予測BIT:1GETI - アナリストの将来予測と過去の財務データ ( )SEK Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/202838,5093,7364,2825,849912/31/202736,7103,3133,5415,0261012/31/202635,0102,8103,4664,952103/31/202634,0922,3593,3164,585N/A12/31/202534,9692,2582,6353,949N/A9/30/202535,8542,0543,1374,434N/A6/30/202535,4981,4902,7044,030N/A3/31/202535,5661,4792,4843,798N/A12/31/202434,7591,6383,2684,577N/A9/30/202433,5911,6912,5663,862N/A6/30/202433,3282,5843,2794,593N/A3/31/202432,1992,2853,2634,633N/A12/31/202331,8272,4121,6042,957N/A9/30/202330,4232,2511,3202,654N/A6/30/202329,7562,1541,2522,519N/A3/31/202329,2512,5431,1052,293N/A12/31/202228,2922,4912,2313,367N/A9/30/202227,7812,7072,8353,916N/A6/30/202227,1462,6653,0854,135N/A3/31/202227,0622,8604,1885,173N/A12/31/202127,0492,9705,6306,560N/A9/30/202127,9003,2926,5857,533N/A6/30/202129,5713,9166,8937,811N/A3/31/202129,9553,6127,0217,988N/A12/31/202029,8193,2396,1547,199N/A9/30/202029,4783,0505,2186,336N/A6/30/202027,7381,8784,2395,437N/A3/31/202027,0441,4873,4614,690N/A12/31/201926,5591,222N/A3,832N/A9/30/201925,9511,030N/A2,836N/A6/30/201925,398-632N/A3,082N/A3/31/201924,852-654N/A2,592N/A12/31/201824,172-967N/A2,503N/A9/30/201823,653-727N/A2,899N/A6/30/201822,914847N/A2,371N/A3/31/201822,552676N/A2,193N/A12/31/201722,4951,096N/A2,763N/A9/30/201717,061596N/A3,466N/A6/30/201719,046390N/A3,599N/A3/31/201720,604701N/A3,839N/A12/31/201622,170698N/A3,671N/A9/30/201629,6501,203N/A3,372N/A6/30/201629,6461,462N/A3,369N/A3/31/201629,9001,410N/A3,504N/A12/31/201530,2351,390N/A3,458N/A9/30/201529,3031,429N/A3,366N/A6/30/201528,6031,622N/A3,386N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: 1GETIの予測収益成長率 (年間11.8% ) は 貯蓄率 ( 3.3% ) を上回っています。収益対市場: 1GETIの収益 ( 11.8% ) はItalian市場 ( 11.3% ) よりも速いペースで成長すると予測されています。高成長収益: 1GETIの収益は増加すると予測されていますが、大幅には増加しません。収益対市場: 1GETIの収益 ( 4.4% ) Italian市場 ( 5.8% ) よりも低い成長が予測されています。高い収益成長: 1GETIの収益 ( 4.4% ) 20%よりも低い成長が予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: 1GETIの 自己資本利益率 は、3年後には低くなると予測されています ( 10.6 %)。成長企業の発掘7D1Y7D1Y7D1YHealthcare 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/09 19:48終値2026/06/09 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Getinge AB (publ) 10 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。24 アナリスト機関null nullABG Sundal CollierScott BardoBerenbergDelphine Le LouetBernstein21 その他のアナリストを表示
お知らせ • Oct 21Getinge AB (Publ) Reaffirms Earnings Guidance for the Year 2025Getinge AB (publ) reaffirmed earnings guidance for the year 2025. The company remain with expectation for organic net sales growth to be in the range of 2% to 5% and long-term financial target of over 12% EPS growth is also intact despite the headwind from tariffs and currency.
お知らせ • Jun 04Getinge Launches Vasoview Hemopro 3 Endoscopic Vessel Harvesting SystemGetinge announced the launch of the Vasoview Hemopro 3 Endoscopic Vessel Harvesting (EVH) System, including the Hemopro 3 Harvesting Tool and dedicated Hemopro 3 Power Supply. The system represents the latest evolution of Getinge's EVH platform, enhancing decades of experience supporting coronary artery bypass grafting (CABG) procedures. Endoscopic vessel harvesting is a minimally invasive technique used to obtain blood vessels, most commonly the saphenous vein or radial artery, for use in CABG surgery. Vessel harvesting plays a critical role in procedural success, as conduit quality and incision-related complications can significantly impact outcomes and recovery. Compared with traditional open harvesting methods, EVH has been associated with reduced wound complications, less postoperative pain, faster recovery, and improved cosmetic results. Getinge has completed an Initial Launch of the Vasoview Hemopro 3 EVH System and has received valuable, positive customer feedback. Getinge has continuously refined EVH technology with a focus on preserving conduit quality while improving the patient and clinician experience. Through close collaboration with vessel harvesting specialists, Getinge has advanced EVH technology in a deliberate, user-driven way, ensuring solutions evolve alongside clinical practice. The Vasoview Hemopro 3 system incorporates targeted enhancements across ergonomics, energy control, visualization, and workflow efficiency, informed by input from more than 100 vessel harvesting specialists worldwide. A redesigned Harvesting Tool features an ergonomic, game-controller-style handle and a soft-touch Activation Toggle that allows activation with minimal force and multiple hand positions, supporting clinician comfort and control throughout the procedure. The system also introduces simplified connectivity through an integrated Harvesting Tool Power Cable, providing a one-click connection to the new Vasoview Hemopro 3 Power Supply and eliminating the need for extension cable sterilization. The dedicated Power Supply is designed to deliver consistent energy and promote efficient cut-and-cautery performance with minimal downtime. Hemopro 3 includes features which support consistent visibility, safety, and workflow efficiency during EVH. Vasoview Hemopro 3 is launching in the U.S., with a training supported rollout available for U.S. customers. Getinge plans a phased expansion outside the U.S., with availability in additional markets to follow based on regulatory approvals and market readiness. Vasoview Hemopro 2 will continue to be available as Getinge rollout availability of Vasoview Hemopro 3.
Recent Insider Transactions • May 31CEO, President & Director recently bought €436k worth of stockOn the 29th of May, Mattias Perjos bought around 25k shares on-market at roughly €17.43 per share. This transaction amounted to 12% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Mattias has been a buyer over the last 12 months, purchasing a net total of €715k worth in shares.
Valuation Update With 7 Day Price Move • May 22Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to €18.75, the stock trades at a forward P/E ratio of 18x. Average forward P/E is 19x in the Medical Equipment industry in Italy. Total returns to shareholders of 8.3% over the past year. Simply Wall St's valuation model estimates the intrinsic value at €32.79 per share.
New Risk • May 15New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Italian stocks, typically moving 7.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (7.2% average weekly change).
お知らせ • Apr 22+ 1 more updateGetinge AB (publ) Approves Dividend, Payable from April 28, 2026Getinge AB (publ) approved the Dividend payment at its Annual General Meeting held on April 21, 2026. In accordance with the proposal by the Board of Directors and the CEO, the AGM resolved to declare a dividend of SEK 4.75 per share. April 23, 2026 was determined as record date for dividend. The dividend is expected to be distributed by Euroclear Sweden AB starting April 28, 2026.
お知らせ • Apr 10Getinge AB (publ) (OM:GETI B) acquired Pennamed Limited.Getinge AB (publ) (OM:GETI B) acquired Pennamed Limited on April 8, 2026. The acquisition strengthens Getinge’s offering to endoscopy units across the United Kingdom (UK) by combining Pennamed’s established consumables portfolio and strong customer relationships with Getinge’s expertise in endoscope reprocessing, infection control, and washer-disinfector technology. Getinge and Pennamed has combined 350 employees. Abi Godfrey, Alex Parry and Matt Harvey of Grant Thornton UK LLP acted as accountants for Pennamed Limited. Emma Orriss and Nigel Beckwith of Gosschalks LLP acted as legal advisors for Pennamed Limited. Covington & Burling Llp acted as legal advisor and Ernst & Young AB acted as accountant for Getinge AB. Getinge AB (publ) (OM:GETI B) completed the acquisition of Pennamed Limited on April 8, 2026.
お知らせ • Mar 26+ 3 more updatesGetinge AB (publ) to Report Q2, 2026 Results on Jul 17, 2026Getinge AB (publ) announced that they will report Q2, 2026 results on Jul 17, 2026
お知らせ • Mar 12Getinge AB (publ) Announces Malin Persson Declines Re-Election as Board Member, Effective April 21, 2026Getinge AB (publ) at its Annual General Meeting to be held on April 21, 2026, announced Malin Persson has declined re-election as board member.
Declared Dividend • Feb 24Dividend of kr4.75 announcedShareholders will receive a dividend of kr4.75. Ex-date: 22nd April 2026 Payment date: 28th April 2026 Dividend yield will be 25%, which is higher than the industry average of 1.7%. Sustainability & Growth Dividend is covered by both earnings (57% earnings payout ratio) and cash flows (49% cash payout ratio). The dividend has increased by an average of 5.4% per year over the past 10 years. However, payments have been volatile during that time. EPS is expected to grow by 47% over the next 3 years, which should provide support to the dividend and adequate earnings cover.
Board Change • Feb 24Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 4 experienced directors. 7 highly experienced directors. Director Ulrika Dellby was the last director to join the board, commencing their role in 2025. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Jan 28Getinge AB (publ), Annual General Meeting, Apr 21, 2026Getinge AB (publ), Annual General Meeting, Apr 21, 2026.
お知らせ • Jan 27Getinge AB (Publ) Proposes DividendGetinge AB (publ) announced the proposal of dividend per share of SEK 4.75 (4.60).
お知らせ • Dec 19Getinge AB Announces Malin Persson Declines Re-Election to the BoardGetinge AB announced that Malin Persson, a board member since 2014, has announced that she will not be available for re-election to the board in 2026.
Board Change • Dec 11Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 4 experienced directors. 7 highly experienced directors. Director Ulrika Dellby was the last director to join the board, commencing their role in 2025. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Board Change • Nov 19Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 4 experienced directors. 7 highly experienced directors. Director Ulrika Dellby was the last director to join the board, commencing their role in 2025. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Oct 21Getinge AB (Publ) Reaffirms Earnings Guidance for the Year 2025Getinge AB (publ) reaffirmed earnings guidance for the year 2025. The company remain with expectation for organic net sales growth to be in the range of 2% to 5% and long-term financial target of over 12% EPS growth is also intact despite the headwind from tariffs and currency.
Reported Earnings • Jul 21Second quarter 2025 earnings released: EPS: kr1.92 (vs kr1.88 in 2Q 2024)Second quarter 2025 results: EPS: kr1.92 (up from kr1.88 in 2Q 2024). Revenue: kr8.24b (flat on 2Q 2024). Net income: kr524.0m (up 2.1% from 2Q 2024). Profit margin: 6.4% (up from 6.2% in 2Q 2024). Revenue is forecast to grow 4.6% p.a. on average during the next 3 years, compared to a 6.5% growth forecast for the Medical Equipment industry in Italy.
お知らせ • Jul 02Getinge AB (publ)(OM:GETI B) dropped from OMX Stockholm 30 IndexGetinge AB (publ) has been dropped from the OMX OMX Stockholm 30 Index
お知らせ • Apr 23+ 1 more updateGetinge AB (publ) Approves Dividend, Payable on April 29, 2025Getinge AB (publ) at its AGM held on April 22, 2025 approved dividend of SEK 4.60 per share. April 24, 2025 was determined as record date for dividend. The dividend is expected to be distributed by Euroclear Sweden AB starting Tuesday April 29, 2025.
お知らせ • Mar 28+ 1 more updateGetinge AB (publ) to Report Q3, 2025 Results on Oct 21, 2025Getinge AB (publ) announced that they will report Q3, 2025 results on Oct 21, 2025
お知らせ • Mar 18Getinge Introduces Neural Pressure Support for the Servo-U Ventilator SystemGetinge announces the launch of its latest innovation in ICU ventilation – Neural Pressure Support (NPS) – available for both invasive and non-invasive ventilation. Building on its most personalized ventilation modes, NAVA and NIV NAVA, these two new NPS modes offer clinicians more options to provide personalized ventilation that aims to protect both the lungs and diaphragm. For years, Getinge has been market-driving when it comes to developing first-of-its-kind intensive care ventilation modes. The medtech company is introducing NPS and NIV NPS to widen its neurally controlled ventilation offering. The new Neural Pressure Support modes give clinicians the opportunity to deliver classical pressure support ventilation, enhanced with neural trigger and breath termination in synchrony with diaphragmatic muscle activity. This may be particularly beneficial for complex and challenging ICU patient groups, such as obstructive COPD patients requiring instant synchronization and fast pressurization, and restrictive ARDS patients with stiff lungs and an excessive respiratory drive.
お知らせ • Jan 29Getinge AB (publ), Annual General Meeting, Apr 22, 2025Getinge AB (publ), Annual General Meeting, Apr 22, 2025. Location: halmstad Sweden
お知らせ • Dec 10Getinge AB (publ) to Report Q1, 2025 Results on Apr 22, 2025Getinge AB (publ) announced that they will report Q1, 2025 results on Apr 22, 2025